Please assess the completion status of the following clinical trial:

Trial Title: Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients, ages 18 years or older who have signed the informed consent~* Has a qualifying skin and skin structure infection~* Female patients must not be pregnant at the time of enrollment~* Must agree to a reliable method of birth control during the study and for 30 days following the last dose of study drug~Exclusion Criteria:~* Infections where the outcome is strongly influenced by factors other than protocol-defined treatments and procedures, or that require antibacterial treatment for greater than 14 days~* Evidence of significant immunological disease~* Severe renal disease or requirement for dialysis~* Evidence of septic shock~* Has a history of hypersensitivity or allergic reaction to any tetracycline or to linezolid~* Has received an investigational drug within the past 30 days~* Women who are pregnant or nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Omadacycline (Type: EXPERIMENTAL): Omadacycline tablets
- Linezolid (Type: ACTIVE_COMPARATOR): Linezolid tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).